Basic Information
| LncRNA/CircRNA Name | XIST |
| Synonyms | XIST, DXS1089, DXS399E, LINC00001, NCRNA00001, SXI1, swd66 |
| Region | GRCh38_X:73820651-73852753 |
| Ensemble | ENSG00000229807 |
| Refseq | NR_001564 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | autophagy0 | Drug | Cisplatin | |
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | non small cell lung cancer |
| ICD-0-3 | C34 |
| Methods | qPCR, Western blot |
| Sample | non-small cell lung cancer tissues |
| Expression Pattern | up-regulated |
| Function Description | lncRNA-XIST was overexpressed in NSCLC tumor samples, and knockdown of lncRNA-XIST significantly decreased autophagy by regulation of ATG7.miR-17 was upregulated following knockdown of lncRNA-XIST, and miR-17 mimics decreased the protein levels of ATG7 by directly targeting the 3'-untranslated region of ATG7 mRNA. the expression level of lncRNA-XIST was markedly increased in cisplatin-resistant A549 cells. Knockdown of lncRNA-XIST restored the chemosensitivity of cisplatin-resistant A549-cells to cisplatin, which was reversed by miR-17 inhibitor and overexpression of ATG7. lncRNA-XIST may be a potential marker of poor response to cisplatin chemotherapy in NSCLC patients and the pathway 'lncRNA-XIST/miR-17/autophagy' may be a promising target for patients with chemoresistant NSCLC. |
| Pubmed ID | 29130102 |
| Year | 2017 |
| Title | Knockdown of lncRNA-XIST enhances the chemosensitivity of NSCLC cells via suppression of autophagy. |
External Links
| Links for XIST | GenBank HGNC NONCODE |
| Links for non small cell lung cancer | OMIM COSMIC |